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Objectives To determine the relative and absolute reliability of the 
assessment of ambulatory walking activity during 2 consecutive weeks in 
patients with hematologic malignancies recovering at home from their medical 
treatment and to compare the physical activity level of hematologic cancer 
patients after high-dose chemotherapy with healthy subjects. Design Test-
retest study of 2 consecutive 7-day recordings using the microprocessor 
based step accelerometer 3 (SAM3). Setting Home and community. 
Participants Patients (n=23) with hematologic malignancies recovering from 
high-dose chemotherapy and healthy controls (n=30). Interventions Not 
applicable. Main Outcome Measures The intraclass correlation coefficient 
(ICC3,1) and its 95% confidence interval (CI), SE of measurement procedure 
and its 95% CI, the smallest detectable difference (SDD), the coefficient of 
variation (CV), and t tests for the variables total steps and peak activity. 
Results The day-to-day and week-to-week CVs for walking activity and peak 
activity were 35.17% and 13.17% and 18.61% and 6.90%, respectively. For 
relative reliability, the ICCs for 2 consecutive 7-day recordings including the 
95% CI for total steps and peak activity were 0.90 (95% CI, 0.75 - 0.98) and 
0.85 (95% CI, 0.66 - 0.94), respectively. The absolute reliability for total steps 
and peak activity including the SE of measurement procedure and the 95% CI 
were 564 (95% CI, + 1106) and 2.42 steps (95% CI, + 4.74), respectively, for 
2 consecutive 7-day recordings. The week-to-week SDD was 1564 for total 
steps and 6.70 for peak activity. The 7-day mean for total step activity was 
5355 for the patients with hematologic malignancies and 6364 for healthy 
subjects (P<0.05). Conclusions The results of this study indicate that there is 
good relative reliability for the assessment of 2 consecutive 7-day recordings 
of ambulatory walking activity, and it showed that the SDD derived from this 
sample may be useful in detecting changes in daily walking activity in 
hematologic cancer patients who are recovering from intensive medical 
treatment. The study also documented compromised levels of ambulatory 
walking activity among hematologic cancer patients recovering from high-
dose chemotherapy as compared with healthy controls. 
Key words Hematologic neoplasms; Physical activity; Rehabilitation; 
Technology assessment; Walking. 
Introduction 
 
The intensive medical treatment of patients with hematologic malignancies [1-
7] is associated with numerous long-term adverse effects, including anemia, 
fatigue, and reduced physical exercise capacity. [8] Fatigue may compromise 
general activity, work, enjoyment of life, mood, walking, and relationships with 
others even for a length of time after medical treatment [9-11] is completed. 
It has been shown that patients with hematologic malignancies may 
benefit from physical exercise programs in terms of maintenance or even 
improvement in fatigue, physical activity, and fitness levels. [12-14] A major 
component of daily physical activity and the most common form of exercise is 
walking. [15] Walking is self regulated in intensity, duration, and frequency 
and can be an important indicator of a person’s health and fitness status.[16] 
The improvement of functional status is a primary goal in the rehabilitation of 
cancer patients. [17,18] It is thus important to be able to document 
quantitatively the walking activity of patients who are recovering from 
intensive medical treatment. An understanding of the quantity (or lack) of 
walking activity seems particularly important in addressing the needs of 
cancer patients who are recovering from intensive medical treatment. 
Daily walking activity can be assessed by means of self-report diaries, 
questionnaires, or objective performance indicators. Self-report measures of 
walking activity have been reported to be imprecise compared with objective 
measures. [19,20] Relatively new techniques allowing unobtrusive long-term 
activity monitoring with the use of pedometers and microprocessor-based 
accelerometer recorders may provide a clearer view of how much an 
individual actually walks in his/her own surroundings. [21] However, the major 
limitations of many pedometers are their accuracy and reliability [21,22] 
because they are worn at the waist and thus are sensitive to vertical 
movement. Therefore, the response may be affected by position, mode of the 
pedometer attachment, movement style, and walking speed of the individual 
being monitored. [21,22] Microprocessor-based accelerometers are 
developed to overcome the limitations of waist-attached devices because 
settings can be adapted according to height, cadence, and the walking style 
of the subject. [22]  
The accuracy of these devices has consistently been reported to be 
above 98%. [23] Most studies of the test-retest reliability of walking activity 
have reported only relative reliability, such as the ICCs (varying from 0.84 to 
0.97). [19-21,23-28] These statistics indicate the degree of association 
between 2 or more measures, [29] but they do not provide clinical guidance 
for assessing real changes. [30,31] Absolute reliability reflects the magnitude 
of the differences between 2 measures. [32] Examples of these statistics are 
the SE of measurement procedure and the SDD. [33,34] to be clinically 
useful, an assessment procedure must have a small measurement error to 
detect a real change. A test-retest difference in a patient with a value smaller 
than the SE of measurement is likely to be the result of measurement noise 
and is unlikely to be detected reliably in practice; a difference greater than the 
smallest real difference is highly likely (with 95% confidence) to be a real 
difference. [35] To date, there is no empiric evidence to guide the clinical 
assessment of real changes in long-term ambulatory walking activity in 
hematologic cancer patients who are recovering from intensive medical 
treatment in their home environment. 
Additionally, to date, no study has attempted to quantitatively document 
the long-term, ambulatory walking activity of hematologic cancer patients after 
treatment compared with the ambulatory walking activity of healthy subjects. 
Among healthy individuals, 10,000 steps daily has been estimated to be of 
value in maintaining desired health benefits. [36] However, preliminary 
evidence suggests that a goal of 10,000 steps daily may not be sustainable 
for some groups, including older adults and those living with chronic diseases. 
[28,36] This finding is supported by the results of a recently published meta-
analysis by Bohannon [37] that provided an estimate of the number of daily 
steps taken by adults. The results of this meta-analysis suggested that the 
general number of daily steps taken was less than the recommended 10,000 
steps a day and that walking activity was especially low in adults 65 years of 
age or older. In 1 study, [21] the mean 7-day step counts of healthy subjects 
(6929 steps; range, 4347–10,002 steps) was significantly greater (P<0.001) 
than that of patients with multiple sclerosis (2985 steps; range, 689 - 5340 
steps), Parkinson disease (3818 steps; range, 1611–5391 steps), or muscular 
disorders (3003 steps; range, 716 - 5302 steps). The purpose of this study 
was to determine the relative and absolute reliability of the assessment of 
ambulatory walking activity during 2 consecutive weeks in patients with 
hematologic malignancies recovering at home from their medical treatment 
and to compare the physical activity level of hematologic cancer patients after 






Patients with a diagnosis of hematologic cancer who had completed 
treatment with high-dose chemotherapy were selected to participate in the 
study from the Departments of Oncology and Hematology of the University 
Hospital Zurich. Patients were excluded from the study if they were  
experiencing the direct side effects of high-dose chemotherapy (eg, fever, 
hemoglobin level <10g/dL, emesis, dyspnea, < 36 of 52 points on the FACT-F 
subscale [38]) in case of gait abnormalities, known impairment of the lower 
limbs, severe GVHD except for grade 1 not requiring treatment, painful joints, 
instable osteolyses of the vertebrae, chronic low back pain, lesions of the 
central or peripheral nervous system, uncontrolled cardiovascular disease, 
thyroid disease, or diabetes. The patients’ walking activity levels were 
compared with those of 30 subjects without known physical impairments, 
injuries, or other health-related conditions that hampered walking activity. An 
inverse correlation has been reported between walking activity, higher BMI, 
[39] and increased age. [40] Therefore, the healthy subjects were matched for 
age (years + 5), sex, and BMI (BMI + 3kg/m2) (table 1) with the patients. The 
healthy subjects were recruited, at random, from the hospital’s employees, 
including laboratory assistants (n=6), nurses (n=5), physical therapists (n=5), 
administrative personnel (n=6), physicians (n=1), researchers (n=4), dieticians 
(n=1), and technicians (n=2). All participants provided written informed 




Height was assessed to the nearest 0.5cm with a wall fixed tape 
measure and weight to the nearest 0.5kg (SECA weighting machine, Model 
791a). Hemoglobin values (g/dL) were determined at the time of an outpatient 
visit, and self-reported fatigue was assessed with the German language 
version of the 13-item FACT-F Version 4. [41] This scale includes items 
relating to both the symptoms and consequences of fatigue and has test-
retest reliability (r=0.90). [41] Hemoglobin values and self-reported fatigue 
were measured because both factors (ie, low hemoglobin levels and high 
fatigue levels) can have adverse effects on physical performance over time. 
[42] 
 
Step activity monitoring 
Step activity levels were assessed with the SAM3.b The SAM3 measures 75 x 
50 x 20mm and weighs approximately 38g. Settings of the SAM3 can be 
adapted according to the height, cadence, and walking style of the individual. 
[16] The SAM3 does not allow adjustment and does not require maintenance 
by the user. The SAM3 is worn on the right lateral or the left medial malleolus. 
It is contoured to fit comfortably against the leg (figure 1). An elastic 
attachment strap ensures that the monitor remains securely attached to the 
ankle without irritating the skin. The SAM3 continuously records the number of 
steps per time interval. The device is programmed and downloaded onto a 
host computer via a universal serial bus docking station. Programming and 
downloading are performed with the StepWatch Analysis Software.b 
Information that was routinely recorded in the standard programming mode 
included the following individual gait characteristics: cadence, speed, the total 
length of time of the data collection (7 days), and individual identifying 
information. The device was calibrated by programming estimated values for 
walking cadence and speed based on the subject’s height (patient’s or healthy 
subject’s) into the computer before providing the SAM3 to the subject. The 
subject was then instructed to walk at a normal preferred speed for 20m. The 
steps of the right leg were counted manually by an observer and compared 
with those of the SAM3. This procedure was repeated if there was a 
difference of 2 steps or more between the manual count and that of the step 
watch monitor. If the manual counting was lower than that of the step monitor, 
the programmer decreased the value of the cadence of the SAM3. If the 
manual count remained too high, the sensitivity of the SAM3 was decreased 
by the programmer. [16] 
 
Recording procedures of the SAM3 
Patients and healthy controls were instructed to wear the SAM3 for 7 
consecutive days, excluding sleep time. Activity monitoring over a 7-day 
period has previously been found to result in reliable and representative 
measures of an individual’s movements on a day-to-day basis. [21] All 
participants were instructed to leave the SAM3 on the ankle if they had to rest 
or lay down during the day and to perform their daily activities as usual. After  
7 days, the participants returned to the hospital, where the data were 
downloaded into a database. For patients, this procedure was repeated for a 
second consecutive 7-day period. When returning the step monitor, we asked 
the patients if they changed their walking behavior because of health related 
factors during the 2-week recording time. The walking activity of healthy 
controls was measured for the initial consecutive 7-day period only.  
 
SAM3 parameters 
The parameters assessed by the SAM3 for this study were (1) total steps a 
day and (2) the peak activity index (the maximum number of steps recorded 
per time interval for each day). 
 
Statistical analyses 
Normality of the data was tested with the Kolmogorov-Smirnov test. [43] Data 
were analyzed by using the ICC3.1, with 95% CI. [29] An ICC greater than 
0.75 was defined as high reliability. [29]  
The SE of measurement procedure was calculated from the average 
known SD and the relative reliability coefficient (r) of the measurement 
procedure used for our sample: SE of measurement procedure =SD(1-r). 
[29,34,44,45] The corresponding 95% CI, in which the true score (drawn from 
the normally distributed population) is expected, was +1.96 x SE of 
measurement procedure. [46-48] The broader the limits of the 95% CI, the 
less confident the estimation of the true score and, as a consequence, the 
less confident the detection of the real change because of intervention. [45] 
This knowledge about the SE of measurement procedure is necessary before 
one can say that such a change has occurred. [46,49] Moreover, when 
analyzing a difference between 2 consecutive observations, one must 
consider the SE of measurement procedure of the observed score for both the 
first week of walking activity (SE of measurement procedure [first week]) and the 
second-week (SE of measurement procedure [second week]) observations. The 
SDD is known as the measure of statistically significant change between 2 
independently obtained measurements. Given a probability value of alpha 
equal to 0.05 as indication for statistical significance, the SDD is estimated as 
1.96 x (SE of measurement procedure [first week]2 + SE of measurement 
procedure [second week]2). [31] Assuming that the SE of measurement procedure 
of the observed score of the first and second observations is equal, the SDD 
is 1.96 x 2 x SE of measurement procedure. For a statistically significant 
change between 2 separate observations to be detected, this change must be 
at least the SDD of the measurement procedure. [34]  
We determined CV (SD/mean x 100%) to examine the individual day-
to-day and week-to-week within-subject variability for walking activity (table 2) 
in hematologic cancer patients. [29] Differences between patients’ means for 
total steps and peak activity were calculated with a paired Student t test to 
quantify the systematic error (also known as bias) of the step activity monitor. 
Differences between the patients’ and the healthy participants’ means for total 
steps and peak activity were determined with an independent sample t test. 
[29] All statistical analyses were performed by using SPSS 12.0.1 for 
Windowsc and Excel 2003 for Windows.d 
 
Results 
Forty-nine adult patients with a diagnosis of hematologic cancer who had 
completed treatment with high-dose chemotherapy were selected. Five 
patients were excluded because of low hemoglobin values and/or severe 
fatigue, and 14 patients were not interested in participating. Specifically, the 
study sample (n=30) consisted of 14 leukemia patients treated with induction 
chemotherapy after peripheral blood stem cell transplantation, 11 non-
Hodgkin lymphoma patients treated with high-dose chemotherapy alone (n 
=10) or high-dose chemotherapy after autologous stem cell transplantation 
(n=1), and 4 multiple myeloma/plasmacytoma patients treated with high-dose 
chemotherapy alone (n=3) or high-dose chemotherapy after 2 cycles of 
autologous stem cell transplantation (n=1). All patients participating were in a 
physically stable condition. Seven of the 30 patients (23%) did not wear the 
SAM3 consistently during the 7-day period (during waking hours) and were, 
for that reason, excluded from the analyses. None of the patients reported 
change in walking behavior because of health-related factors. Thus, the final 
analysis was performed in 23 patients (12 women/11 men) (see table 1). The 
accuracy of the SAM3 was 98% in this study based on a comparison of the 
number of steps counted by the SAM3 with the observed steps after the 
cadence had been identified. All results of the step activity measurements and 
the difference for step activity measurements between week 1 and week 2 
were normally distributed. 
The ICCs including the 95% CI for total steps and peak activity were 
0.90 (95% CI, 0.75 - 0.98) and 0.85 (95% CI, 0.66 - 0.94), respectively. The 
absolute reliability for total steps and peak activity expressed as the SE of 
measurement procedure including the 95% CI and the SDD was 564 (95% 
+1106) and 2.42 (95% CI + 4.74), respectively. The SDD was 1564 for total 
steps and 6.7 for peak activity. The 7-day measurement period (week 1) 
revealed a day-to-day variability for total steps in hematologic cancer patients 
as follows: a range of 14,903 (minimum 1008, maximum 15,911), a mean + 
SD of 5355 +2678. The day-to-day and week-to-week mean CV for step 
counts was 35.17% and 13.23%, respectively (see table 2). The day-to-day 
and week-to-week mean CV for peak activity was 18.61% and 6.90%, 
respectively. There were no significant changes for the total steps and peak 
activity parameters (table 3) or were there significant changes for the patient 
group in hemoglobin values or self-reported fatigue between weeks 1 and 2. 
The patient group yielded significantly lower mean values for the parameters 




This is the first study that provides clinical guidance for the assessment 
of real changes in long-term day-to-day walking in patients with hematologic 
malignancies after medical treatment. We have used the ICC (with 
accompanying 95% CI) and the CV to estimate relative reliability and the SE 
of measurement procedure (with accompanying 95% CI) and the SDD to 
estimate measurement error. To be of practical use, the results should be 
interpreted as follows: the measurements exhibited good relative reliability 
with an ICC value of 0.9 (95% CI, 0.75 - 0.98), and a CV of 13.23% for the 
variable total steps. 
For the variable peak activity, we estimated an ICC of 0.85 (95% CI, 0.66 - 
0.94) and a CV of 6.9%. Although patients reported that they did not change 
their walking behavior because of changes in health status or symptom 
burden during the 2-week assessment period, the absolute reliability or 
measurement error of this parameter is affected by the relatively large 
variance statistics of the measurements total steps week 1 and week 2, which 
were 3,719,690 and 2,695,540, respectively (calculated as the square of the 
SD week 1 [1928.65] and week 2 [1641.81]). The variance statistics of the 
variable peak activity were 44.89 for week 1 and 42.25 for week 2. When 
taking the measurement error into account (SE of the measure procedure = 
564 for total steps, 2.42 for peak activity), an SDD greater than 1564 total 
steps (or 6.7 for peak activity) between 2 consecutive 7-day measures should 
be interpreted as the real change in patients’ total steps daily activity. It is 
reasonable to assume that a significant increase in both variables after, for 
example, participation in a moderate walking exercise program can be 
measured with the SAM3. Conversely, however, it would not be possible to 
detect a real change in daily total step activity or peak activity if the 
measurement error is larger than the improvement or deterioration in the 
walking activity of the patient. 
Although the SAM3 is a lightweight and unobtrusive device, it is 
remarkable that 23% of the patients did not comply with wearing the step 
monitor consistently during the 2 consecutive weeks. To gather representative 
data, clinicians and researchers should emphasize the importance of the 
measurement protocol to the participant when wearing a step monitor device. 
However, the original data for total step activity in 30 patients with 
hematologic malignancies yielded an equal reliability result for the ICC (0.90). 
The SDD was 2126. The variance statistics for week 1 and week 2 in 30 
patients were 3,342,063 and 3,117,484, respectively. The ICC for peak 
activity in the original 30 patients was 0.88 and the SDD 8.98. The variance 
statistic for week 1 and week 2 in 30 patients was 49.28. For the correctness 
of analysis, we chose to present the data of the 23 complying patients. We 
compared the total daily ambulatory step activity in patients with hematologic 
malignancies with those of age-, sex-, and BMI-matched healthy participants. 
The healthy subjects performed significantly more total daily steps and also 
had a higher peak activity index, which indicated that the healthy subjects 
walked with an overall higher intensity than the cancer patients (see table 4). 
With the improvement of prognosis in hematologic malignancies, walking 
activity may become an important component in continuing care programs 
(eg, for physical activity programs that emphasize walking activity and that 
also consider the intensity of the performed steps as important). Therefore, 
the amount of steps a day and the peak activity index both appear to be of 
particular relevance in the case of patients with hematologic cancer who are 
recovering from systemic treatment because they seem especially suited as 
outcome parameters for intervention studies. 
The findings of our cross-sectional investigation with regard to daily 
walking activity are supported by several earlier studies. Keats et al. [50] 
reported that physical activity significantly declined in adolescents who were 
treated for leukemia and did not return to pretreatment levels after the 
completion of treatment. Florin et al. [51] reported that long-term survivors of 
childhoodleukemia were less likely to meet physical activity recommendations 
and that lowered levels of physical activity increase the risk of cardiovascular 
disease, osteoporosis, and all-cause mortality. Thus, the long-term 
implications of a reduction in physical activity, including daily walking activity, 
may be far reaching for patients with hematologic malignancies. However, 
longitudinal studies are needed to document the changes in physical activity 
level in this population of patients. 
Our reliability results are similar to those observed in other studies. A 
test-retest coefficient of 0.97 was observed in 1 study [19] in which the stride 
counts were counted during a 6-minute walking test. Resnick et al. [24] found 
an ICC value of 0.84 in a test-retest design when comparing 1-minute walks in 
elderly adults. Haeuber et al. [25] reported a reliability of 0.96 when stride 
counts were assessed in a 2- x 24-hour test-retest situation. Finally, Busse et 
al. [21] reported an ICC of 0.86 and 0.89 in neurologic patients and healthy 
persons, respectively, in a 2- x 7-day test-retest design in which daily steps 
were counted. In this study, the day-to-day variability in both healthy 
individuals and those with neurologic impairment was relatively high as 
reflected by the CV. [21] The average CV for day-to-day step counts in 
healthy subjects was 28%, and, in week measures in healthy subjects was 
8.8%, and, in neurologic patients, it was 12%. [21] The healthy subjects 
(mean age, 47y) in our study walked 6363 steps during a consecutive 7-day 
period. This performance is comparable with the study of Busse et al,21 in 
which healthy subjects (mean age, 43y) were reported to walk 6520 steps 
daily. On the other hand, a meta-analyses of Bohannon [37] provided a daily 
step count average of 9448 steps (95% CI, 8899 - 9996) taken by healthy 
adults. The average daily step count performance was divided into 2 groups: 
subjects younger than 65 years of age who performed 9797 (95% CI, 9216 - 
10,377) steps daily and adults over 65 years of age who performed on 
average 6565 (95% CI, 4897 - 8233) daily steps. As a result, the participating 
hematologic patients and healthy subjects in our study would be placed in the 
low active (5000 - 7499 steps/day) category for walking activity [36,37] 
together with the adults over 65 years of age from the meta-analyses of 
Bohannon. [37]  
We would like to note that our results should be interpreted with some 
caution. First, measures of unconstrained walking activity directly assess the 
real-life behavior of the study participants who are facing challenges when 
walking at home or in the community. [28] During the measurements, external 
conditions such as weather, [52] suitability of walking activities, or mediators 
of walking activities such as self-efficacy, social support, or decisional balance 
[53] and the health condition of the patients may influence the variation 
observed in walking activity. However, in test situations such as ours, it is 
possible that the participants, both the cancer patients and the healthy 
controls, are motivated to perform more walking activity, despite explicit 
instructions to perform their daily activities as usual and not to perform extra 
physical activity. Yet, it might also be possible that the participating patients in 
our study were healthier than other hematologic cancer patients at this stage 
of their recovery. The main reason for 11 patients not to participate was that 
they felt too fatigued or too weak. To more fully investigate the multiple 
sources of potential error in assessing daily walking activity, future work 
should address a broader set of reproducibility indicators. In line with the 
generalizability theory, multiple sources of measurement error in walking 
activity to be evaluated include whether patients consistently wear the SAM3 
(ie, adherence), the between- and within subject variation in day-to-day 
walking behavior as a function of the number of hours the SAM3 was worn, 
evidence that the time periods in which walking activity was measured were 
typical, and the possible effect of health-related factors such as fatigue, 
infection, and so on on day-to-day walking activity. Using this generalizability 
approach, reproducibility can be assessed and tailored to the intended 
applications of the SAM3 in cancer patients. [54] 
Second, the point in time at which the patient assessments took place 
varied considerably (see table 1), and, therefore, some patients may have had 
the possibility to recover more from the side effects of high-dose 
chemotherapy than others. This may have influenced the variation observed 
in the day to-day walking activity. However, there are several reasons why we 
believe that the chosen sample of hematologic cancer patients after medical 
treatment was adequate. Our participants were recruited on average 5 
months after medical treatment. None of the patients were in the acute phase 
or experienced the direct side effects of medical treatment. Furthermore, the 
haemoglobin values and the self-reported symptoms of fatigue did not change 
significantly over the measurement period and were therefore indicative for a 
stable physical condition. Nevertheless, one cannot rule out the possibility of a 
changing physical health status during the 2-week period in which the patients 
were observed.  
Third, the cancer patients in our study were compared with a relatively 
select sample of healthy participants working in a university hospital setting. 
As compared with the meta-analyses of Bohannon, [37] other results might 
have emerged if the comparison had been made with individuals without 
known physical impairments, injuries, or health-related conditions that would 
influence walking behavior working in a wider range of settings, including 
individuals who were either not working or had other societal functions (eg, 
students, homemakers, and so on). Despite these caveats, we believe that 
our study provides useful first data regarding the relative reliability of and 
measurement error associated with walking activity as measured with the 
SAM3 when used with hematologic cancer patients and documents the 
sustained deficit in walking activity levels experienced by these patients when 
compared with age- and sex-matched controls. 
 
Conclusions 
This study represents an ongoing process toward developing accurate 
and reliable tools to describe the individual walking performance in the 
patients’ own environment. The results of this study indicate that there is good 
relative reliability for the assessment of 2 consecutive 7-day ambulatory 
walking activity in hematologic cancer patients. This study showed that the 
SDD derived from this sample may be useful in detecting changes in daily 
walking activity in hematologic cancer patients who are recovering from 
intensive medical treatment. The study also documented compromised levels 
of ambulatory walking activity among hematologic cancer patients recovering 
from high-dose chemotherapy as compared with healthy controls.  
 
Acknowledgments  
We thank Pamela Hofer, MSc, and Michèle Hubli, MSc, for instruction in the 
use of the SAM3 and for data management and Leanne Pobjoy for her 
assistance with the English editorial service. We also thank all of the 
physicians from the Department of Medical Oncology and from the 
Department of Hematology, University Hospital of Zurich, for referring patients 
to this study. 
 
References 
1. Koistinen P, Räty R, Itälä M, et al.: Finnish Leukaemia Group. Long-term 
outcome of intensive chemotherapy for adults with de novo acute myeloid 
leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia 
Group. Eur J Haematol 78: 477-486, 2007 
2. Lacy MQ, Gertz MA, Dispenzieri A, et al.: Long-term results of response to 
therapy, time to progression, and survival with lenalidomide plus 
dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82: 1179-1184, 
2007 
3. Okamura J, Uike N, Utsunomiya A, et al.: Allogeneic stem cell 
transplantation for adult T-cell leukemia/lymphoma. Int J Hematol 86: 118-
125, 2007 
4. Toze C, Barnett MJ: Allogeneic haemopoietic stem cell transplantation for 
non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol 15: 481-504, 2002 
5. Axdorph U, Stenke L, Grimfors G, et al., for the Swedish CML Group. 
Intensive chemotherapy in patients with chronic myelogenous leukaemia 
(CML) in accelerated or blastic phase—a report from the Swedish CML 
Group. Br J Haematol 118: 1048-1054, 2002 
6. Estey E, Döhner H: Acute myeloid leukaemia. Lancet 368: 1894-1907, 
2006 
7. Koreth J, Cutler CS, Djulbegovic B, et al.: High-dose therapy with single 
autologous transplantation versus chemotherapy for newly diagnosed multiple 
myeloma: a systematic review and meta-analysis of randomized controlled 
trials. Biol Blood Marrow Transplant 13:183-196, 2007 
8. Evans WJ, Lambert C: Physiological basis of fatigue. Am J Phys Med 
Rehabil 86(1 Suppl):29-46, 2007 
9. Wang XS, Giralt SA, Mendoza TR, et al.: Clinical factors associated with 
cancer-related fatigue in patients being treated for leukemia and non-
Hodgkin’s lymphoma. J Clin Oncol 20: 1319-1328, 2002 
10. Hjermstad MJ, Evensen SA, Kvaløy SO, et al.: Health-related quality of 
life 1 year after allogeneic or autologous stem-cell transplantation: a 
prospective study. J Clin Oncol 17:706-718, 1999 
11. Hjermstad MJ, Knobel H, Brinch L, et al.: A prospective study of health-
related quality of life, fatigue, anxiety and depression 3-5 years after stem cell 
transplantation. Bone Marrow Transplant 34: 257-266, 2004 
12. Dimeo F.: Exercise for cancer patients: a new challenge in sports 
medicine. Br J Sports Med 34:160-161, 2000 
13. Dimeo F, Schmittel A, Fietz T, et al.: Physical performance, depression, 
immune status and fatigue in patients with haematological malignancies after 
treatment. Ann Oncol 15:1237-1242, 2004 
14. Hayes SC, Davies PS, Parker TW, et al.: Role of a mixed type, moderate 
intensity exercise programme after peripheral blood stem cell transplantation. 
Br J Sports Med 38: 304-309, 2004 
15. Manson JE, Greenland P, LaCroix AZ, et al. : Walking compared with 
vigorous exercise for the prevention of cardiovascular events in women. N 
Engl J Med 347: 716-725, 2002 
16. McDonald CM, Widman L, Abresch RT, et al.: Utility of a step activity 
monitor for the measurement of daily ambulatory activity in children. Arch 
Phys Med Rehabil 86: 793-801, 2005 
17. Brown JK, Byers T, Doyle C, et al.: Nutrition and physical activity during 
and after cancer treatment: an American Cancer Society guide for informed 
choices. CA Cancer J Clin 53:268-291, 2003 
18. Knols R, Aaronson NK, Uebelhart D, et al. : Physical exercise in cancer 
patients during and after medical treatment: a systematic review of 
randomized and controlled clinical trials. J Clin Oncol 23: 3830-3842, 2005 
19. Macko RF, Haeuber E, Shaughnessy M, et al.: Microprocessor based 
ambulatory activity monitoring in stroke patients. Med Sci Sports Exerc 34: 
394-399, 2002 
20. Smith DG, Domholdt E, Coleman KL, et al.: Ambulatory activity in men 
with diabetes: Relationship between self-reported and real-world 
performance-based measures. J Rehabil Res Dev 41: 571-580, 2004 
21. Busse ME, Pearson OR, Van Deursen R, et al. : Quantified measurement 
of activity provides insight into motor function and recovery in neurological 
disease. J Neurol Neurosurg Psychiatry 75: 884-88, 2004 
22. Shepherd EF, Toloza E, McClung CD, et al.: Step activity monitor: 
increased accuracy in quantifying ambulatory activity. J Orthop Res 17:703-
708, 1999 
23. Coleman KL, Smith DG, Boone DA, et al.: Step activity monitor: long-term, 
continuous recording of ambulatory function. J Rehabil Res Dev 36: 8-18, 
1999 
24. Resnick B, Nahm ES, Orwig D, et al.: Measurement of activity in older 
adults: reliability and validity of the Step Activity Monitor. J Nurs Meas 9: 275-
290, 2001 
25. Haeuber E, Shaughnessy M, Forrester LW, et al.: Accelerometer 
monitoring of home- and community-based ambulatory activity after stroke. 
Arch Phys Med Rehabil 85: 1997-2001, 2004 
26. Busse ME, Wiles CM, van Deursen RM: Community walking activity in 
neurological disorders with leg weakness. J Neurol Neurosurg Psychiatry 77: 
359-362, 2006 
27. Song KM, Bjornson KF, Cappello T, et al.: Use of the StepWatch activity 
monitor for characterization of normal activity levels of children. J Pediatr 
Orthop 26: 245-249, 2006 
28. Cavanaugh JT, Coleman KL, Gaines JM, et al.: Using step activity 
monitoring to characterize ambulatory activity in community-dwelling older 
adults. J Am Geriatr Soc 55:120-124, 2007 
29. Portney L, Watkins M: Foundations of clinical research. Applications 
to practice. 1st ed. Norwalk: Appleton and Lang; 1993. 
30. de Vet HC, Terwee CB, Knol DL, et al.: When to use agreement versus 
reliability measures. J Clin Epidemiol 59:1033-1039, 2006 
31. Guyatt G, Walter S, Norman G: Measuring change over time: assessing 
the usefulness of evaluative instruments. J Chronic Dis 40: 171-178, 1987 
32. Liaw LJ, Hsieh CL, Lo SK, et al.: The relative and absolute reliability of 
two balance performance measures in chronic stroke patients. Disabil Rehabil 
30: 656-661, 2008 
33. Bowden MG, Behrman AB: Step activity monitor and test re-test reliability 
in persons with incomplete spinal cord injury. J Rehabil Res Dev 44: 355-362, 
2007 
34. Kropmans TH, Dijkstra PU, Stegenga B, et al.: Smallest detectable 
difference in outcome variables related to painful restriction of the 
temporomandibular joint. J Dent Res 78: 784-789, 1999 
35. Sole G, Hamrén J, Milosavljevic S, et al.: Test-retest reliability of isokinetic 
knee extension and flexion. Arch Phys Med Rehabil 88: 626-631, 2008 
36. Tudor-Locke C, Bassett DR Jr.: How many steps/day are enough? 
Preliminary pedometer indices for public health. Sports Med 34: 1-8, 2004 
37. Bohannon RW: Number of pedometer-assessed steps taken per day by 
adults: a descriptive meta-analyses. Phys Ther 87: 1642-1650, 2007 
38. Palumbo A, Petrucci MT, Lauta VM, et al.: Correlation between fatigue 
and hemoglobin level in multiple myeloma patients: results of a cross-
sectional study. Haematologica 90: 858-860, 2005 
39. Chan CB, Spangler E, Valcour J, et al.: Cross-sectional relationship of 
pedometer-determined ambulatory activity to indicators of health. Obes Res 
11: 1563-1570, 2003 
40. Toupin JM, Dujardin F: Quantitative evaluation of indoor walking activities 
related to age. Eur J Orthop Surg Traumatol 9: 27-30, 1999 
41. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-
An) Scale: a new tool for the assessment of outcomes in cancer anemia and 
fatigue. Semin Hematol 34(3 Suppl 2): 13-19, 1997 
42. Birgegård G, Gascón P, Ludwig H: Evaluation of anaemia in patients with 
multiple myeloma and lymphoma: findings of the European CANCER 
ANAEMIA SURVEY. Eur J Haematol 77: 378-386, 2006 
43. Siegel S, Castellan N: Non-parametric statistics for the behavioural 
sciences. 1st ed. Norwalk-New York: Mcgraw-Hill; 1988. 
44. Cronbach JL, Gleser GC, Nanda H, et al.: The dependability of behavioral 
measurements: theory of generizibility for scores and profiles. New York: John 
Wiley and Sons; 1972. 
45. Ottenbacher KJ, Johnson MB, Hojem M: The significance of clinical 
change and clinical change of significance: issues and methods. Am J 
Occupat Ther 42: 156-162, 1988 
46. Roebroeck ME, Harlaar J, Lankhorst GL: Reliability assessment of 
isometric knee extension measurements with a computerassisted hand-held 
dynamometer. Arch Phys Med Rehabil 79: 442-448, 1998 
47. IJzerman MJ, Baardman G, Van ‘t Hof MA, et al.: Validity and 
reproducibility of crutch force and hearth rate measurements to assess energy 
expenditure of paraplegic gait. Arch Phys Med Rehabil 80: 1017-1023, 1999 
48. de Bruin ED, Rozendal RH, Stüssi E: Reliability of phase-velocity 
measurements of tibial bone. Phys Ther 78: 1166-1174, 1998  
49. Hayes KW: The effect of awareness of measurement error on physical 
therapists confidence in their decisions. Phys Ther 72: 515-525, 1992 
50. Keats MR, Culos-Reed SN, Courneya KS, et al.: An examination of 
physical activity behaviors in a sample of adolescent cancer survivors. J 
Pediatr Oncol Nurs 23: 135-142, 2006 
51. Florin TA, Fryer GE, Miyoshi T, et al.: Physical inactivity in adult 
survivors of childhood acute lymphoblastic leukemia: a report from the 
childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 16: 
1356-1363, 2007 
52. Frank JS, Patla AE: Balance and mobility challenges in older adults: 
implications for preserving community. Am J Prev Med 25 (3 Suppl 2): 157-
163, 2003 
53. Marcus B, Forsyth L: Motivating people to be physically active. 1st ed. 
Champaign: Human Kinetics; 2003. 
54. Roebroeck ME, Harlaar J, Lankhorst GJ: The application of 
generalizability theory to reliability assessment: an illustration using isometric 
force measurements. Phys Ther 73: 386-389, 1999 
 
Suppliers 
a. Hess Medizintechnik AG, Grabenstrasse 2, 8865 Bilten, Switzerland. 
b. Cymatech Corp, 8515 35th Ave NE, Ste C, Seattle, WA 98115. 
c. SPSS Inc. (Switzerland), Schneckenmannstrasse 25 8044 Zurich, 
Switzerland. 




Abbreviations: BMI; body mass index, CI; confidence interval, CV; coefficient 
of variation, FACT-F; Functional Assessment of Cancer Therapy–Fatigue, 
GVHD; graft-versus-host disease, ICC; intraclass correlation coefficient, SDD; 




Figure 1: The StepWatch Activity Monitor 3 (SAM3©, Cymatech Corporation, Seattle, 
WA, USA) is contoured to fit comfortably against the leg. An elastic attachment strap 




Table 1. Descriptive measures 
 Patients with 
hematological  






Mean Age (sd) 47.83 (14.57) 46.20 (11.83) .656 
Mean Height in cm (sd) 173.35 (9.59) 173.47 (9.09) .963 
Mean Weight in kg (sd) 77.95 (12.90) 72.15 (17.03) .377 
Mean BMI in kg/m2 (sd) 25.08 (3.39) 23.80 (4.01) .225 
Mean time (days) (sd) 
since medical 
treatment  
142.65 (68.74) n.a. n.a. 
Fatigue FACT-AN/F 
(sd) 
40.17 (8.28) n.a. n.a. 
Hemoglobin (g/dl) (sd) 12.25 (1.53) n.a. n.a. 
Mean values for patients with hematological malignancies and healthy subjects 
 
Table 2. Day-to-day and week-to-week step counts within hematological patients (n=23) 





mean step count 
Patient Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day7 Wk 1 Wk 2 SD CV % Mean SD CV % 
1 3191 4683 5521 2724 7073 5537 6574 5043 4125 1626.58 32,25 4584 649.43 14,17 
2 2105 5470 3546 4907 3673 4771 3582 4008 3257 1129.63 28,19 3632 530.73 14,61 
3 5317 5142 4055 5506 4737 8161 5201 5446 4653 1289.80 23,69 5049 560.23 11,09 
4 1766 6958 3492 4770 4582 4176 4439 4312 3599 1553.12 36,02 3956 503.86 12,74 
5 1467 2100 3386 7791 7579 8677 5175 5168 6224 2923.80 56,58 5696 746.60 13,11 
6 4519 5284 5742 4853 2916 4172 4106 4513 3746 917.68 20,33 4130 542.25 13,13 
7 3598 15911 12074 13799 9845 9125 12282 10948 9484 3965.88 36,23 10216 1034.70 10,13 
8 4529 4212 7398 6272 5959 3764 8101 5748 6644 1651.25 28,73 6196 633.87 10,23 
9 5616 10566 9350 8588 5508 4130 7150 7273 4699 2332.43 32,07 5986 1819.69 30,40 
10 2038 6052 4786 3768 5090 4023 4979 4391 5583 1278.64 29,12 4987 843.17 16,91 
11 4406 4435 3821 4590 3039 7312 6839 4920 4981 1568.36 31,88 4951 42.93 0,87 
12 3345 6378 4737 6468 4396 2255 7531 5016 4744 1878.22 37,45 4880 192.23 3,94 
13 2675 2613 5033 4673 1403 8206 1822 3775 3310 2381.30 63,08 3543 328.60 9,28 
14 1167 5076 7599 2549 5766 4203 5641 4572 3048 2152.82 47,09 3810 1077.02 28,27 
15 5351 5998 8396 9665 8348 9771 7757 7898 5581 1693.03 21,44 6739 1638.67 24,32 
16 5785 6223 8487 11949 7867 8746 9381 8348 7952 2062.68 24,71 8150 280.01 3,44 
17 2529 7137 11475 5427 6915 4378 7410 6467 5583 2815.80 43,54 6025 625.08 10,37 
18 2635 3432 2180 2981 3163 2911 2686 2855 2324 404.02 14,15 2590 375.68 14,51 
19 2727 1319 2990 4281 4682 2222 1008 2747 4277 1384.18 50,39 3512 1081.97 30,81 
20 4509 7359 6786 4168 7220 5441 5141 5803 5682 1311.00 22,59 5743 85.96 1,50 
21 5790 3298 2960 7792 12884 6451 5683 6408 6028 3324.76 51,88 6218 268.80 4,32 
22 5326 7122 2144 5478 3169 2206 8709 4879 4695 2510.24 51,45 4787 130.41 2,72 
23 3369 2231 1348 3306 2771 2635 2813 2639 3683 690.25 26,16 3161 738.52 23,36 
Mean        5356 4952      
CV           35.17   13.23 
Mean, Standard deviation, and co-efficient of variation (CV%) for 1 week monitoring, and the mean SD and CV of the mean 7day step count for 
weeks 1 and 2 are presented. 
 
 
Table 3. Differences between week 1 and 2 for SAM3© parameters total steps and peak activity including the 95% CI of patients with 
hematological malignancies 
Parameter Week 1 (sd) Week 2 (sd) Mean difference (sd)  
(95%CI) 
p-value  
Total Steps / 24h 5355.52 (1928.65) 4952.39 (1641.81) 
average sd wk 1+2: 1785.23 
 
403.13 (1051.55) 
(-51.59 / 857.85) 
.080  
Peak activity index 43.04 (6.70) 
 
42.63 (6.50) 
average sd wk 1+2: 6.60 
 
0.42 (5.09) 
(-1.78 / 2.62) 
.698 






Table 4. Results of the SAM3, differences between patients with hematological  
malignancies and healthy participants 
Parameter  Mean (Sd) Standard 












(-1957.92 /  
-59.24) 
.038 
Patients  42.74 (6.53) 1.36 Peak activity 
index Healthy 
subjects 49.65 (6.34) 1.15 
-6.90 
(-10.48 /  
-3.33) 
<.001 
Mean (sd), standard error of the mean, mean difference (+95%CI) and significance for SAM3 
parameters (total steps and peak activity index) between patients and healthy subjects. 
Differences between patients and healthy subjects were calculated by means of a t-test. 
